Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)

← catalyst calendar

NCT05555732 · readout in 996 d

Sponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →. With AstraZeneca, Merck Sharp & Dohme LLC.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

1,170estimated

Sites

260

Countries

Argentina, Australia, Austria +26

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-01-11

actual

When the study began enrolling

Primary completion

2029-05-11

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-05-11

estimated

The whole study's end, after follow-up

First posted

2022-09-27

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Non Small Cell Lung Cancer

Interventions

Drug: Datopotamab Deruxtecan — also filed as Dato-DXd
Drug: Pembrolizumab — also filed as KEYTRUDA®
Drug: Pemetrexed — also filed as Alimta, Pemfexy
Drug: Carboplatin
Drug: Cisplatin

Primary outcomes

what the primary-completion date above is the date OF

Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants

measured From randomization until disease progression or death (whichever occurs first), up to approximately 43 months

Progression-free Survival Based on Blinded Independent Central Review in All Randomized Participants who are TROP2 NMR positive

measured From randomization until disease progression or death (whichever occurs first), up to approximately 43 months

Overall Survival in All Randomized Participants

measured From randomization until disease progression or death (whichever occurs first), up to approximately 76 months

Overall Survival in All Randomized Participants who are TROP2 NMR positive

measured From randomization until disease progression or death (whichever occurs first), up to approximately 76 months

Publications

PMID 39469838 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed